Endogenous Opioid Peptides: A Guide to Dermorphin, Deltorphin, Kyotorphin, Nociceptin, and MIF-1

The classical opioid receptors — mu (MOR, OPRM1), delta (DOR, OPRD1), and kappa (KOR, OPRK1) — are Gi/Go-coupled GPCRs that produce analgesia by inhibiting adenylyl cyclase, suppressing voltage-gated calcium channels, and activating inwardly rectifying potassium channels. The net effect is decreased neuronal excitability and reduced neurotransmitter release along pain pathways. MOR is the receptor most targeted by conventional opioid analgesics, including morphine and fentanyl; it also drives respiratory depression, constipation, and the reward signaling implicated in addiction. DOR agonism produces analgesia with a potentially more favorable side-effect profile but can trigger convulsions in some models. KOR agonism produces analgesia with dysphoria rather than euphoria, making selective kappa agonists of interest for addiction-free pain treatment and, separately, for pruritus.

A fourth receptor — the nociceptin/orphanin FQ peptide receptor, or NOP (ORL-1, OPRL1) — is structurally homologous to the classical three but pharmacologically distinct. Classical opioid ligands (morphine, naloxone) have little affinity for NOP, and nociceptin does not bind MOR/DOR/KOR at meaningful concentrations. NOP couples through the same Gi/Go signaling machinery, but its downstream effects depend on anatomical location and physiological context in ways that continue to complicate drug development.

Endogenous ligand families map onto these receptors with varying selectivity. Beta-endorphin is a MOR/DOR dual agonist; enkephalins preferentially activate DOR; dynorphins are KOR-preferring. The peptides covered in this guide extend this picture — some with extreme receptor selectivity (deltorphin for DOR, dermorphin for MOR), others with indirect mechanisms (kyotorphin), and one with a functional receptor that sits outside the classical system entirely (nociceptin/NOP).

Dermorphin was isolated in the 1980s from the skin secretions of Phyllomedusa sauvagei, a South American tree frog. Its seven-amino-acid sequence is H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, and its defining feature is the D-alanine at position 2 — a rare occurrence of a D-amino acid in a vertebrate peptide. This single stereochemical change confers extensive resistance to aminopeptidase cleavage and extends biological activity well beyond what endogenous L-amino-acid opioid peptides can achieve.

Pharmacologically, dermorphin is a potent and selective mu-opioid receptor agonist. In vivo potency estimates place it at roughly 30–40 times that of morphine on a molar basis, with negligible affinity for delta or kappa receptors at therapeutic concentrations. The intracellular consequences are the familiar MOR signature — adenylyl cyclase inhibition, calcium channel suppression, and GIRK potassium channel activation — concentrated in pain-modulating structures such as the dorsal horn and periaqueductal gray.

Dermorphin's most public appearance came from an unintended direction. In 2012, testing detected dermorphin in post-race urine samples from multiple racehorses at United States racetracks. Its potency as an analgesic allowed trained horses to run through musculoskeletal pain, conferring an unfair competitive advantage. Racing regulatory bodies responded with bans and prosecutions. No approved human therapeutic indication exists. Despite more than forty years since its discovery and extensive use as a receptor-characterization tool, dermorphin itself has not progressed to clinical development. Structurally-related analogs such as DALDA have been explored for improved pharmacokinetics and targeted delivery but have not reached approval.

Deltorphin — actually a family that includes deltorphin I, deltorphin II, and dermenkephalin — was isolated from Phyllomedusa skin secretions shortly after dermorphin. The surprise was that these peptides, originating from the same amphibian source as dermorphin, showed the opposite receptor selectivity: exceptional affinity for delta-opioid receptors, with binding several orders of magnitude greater than for MOR. Deltorphin II in particular has become one of the workhorse pharmacological probes for DOR characterization.

Mechanistically, deltorphins are DOR agonists that couple through the same Gi/Go pathway as other classical opioid peptides — inhibiting adenylyl cyclase, reducing neuronal excitability, and modulating neurotransmitter release. What makes the delta-selective class interesting for drug development is that preclinical evidence suggests delta-preferring agonists may produce analgesia with reduced respiratory depression, tolerance, and physical dependence compared with mu-selective agonists. Whether that translates to humans remains an open question; human trials of delta-selective agonists have been limited, and some DOR agonists produced convulsive activity in animal models, complicating translation.

The practical significance of the dermorphin–deltorphin pair is methodological as much as therapeutic. Having naturally-occurring, potent, and highly selective ligands for MOR and DOR allowed generations of receptor pharmacologists to dissect opioid receptor signaling with precision that would have been difficult to achieve using endogenous enkephalins or endorphins alone. As of 2026, no deltorphin-family peptide has advanced to approved clinical use; research applications dominate.

Kyotorphin (Tyr-Arg) was isolated from bovine brain in 1979 and is remarkable for its simplicity. At just two amino acids, it is one of the smallest known neuroactive peptides, yet central administration produces potent naloxone-reversible analgesia. The distribution of kyotorphin in the brain — concentrated in the midbrain, pons-medulla, and dorsal spinal cord — mirrors the regional pattern of morphine sensitivity, supporting a physiological role in endogenous pain modulation.

The mechanistic twist is that kyotorphin does not directly bind mu, delta, or kappa opioid receptors with high affinity. Instead, it appears to stimulate the release of met-enkephalin from nerve terminals, with the released enkephalin then acting on mu and delta receptors to produce analgesia. A specific kyotorphin receptor (KTP-R) coupled to a Gi-type G protein has been proposed but not definitively identified at the molecular level. This indirect mechanism — producing opioid-mediated analgesia without being an opioid receptor agonist itself — gives kyotorphin a distinctive pharmacological identity.

The practical challenge with kyotorphin research has been pharmacokinetic rather than receptor-related. The peptide's plasma half-life is only a few minutes due to rapid hydrolysis by dipeptidases, and blood-brain barrier penetration is limited. Modern research has therefore concentrated on kyotorphin analogs with improved stability and CNS delivery. Separately, kyotorphin has shown antimicrobial activity against bacterial membranes, a mechanism unrelated to analgesia. No kyotorphin-derived therapeutic has advanced to clinical trials, but the peptide remains of academic interest as both a pharmacological tool and a potential scaffold for designed peptide drugs.

Nociceptin — also known as orphanin FQ or N/OFQ — is a 17-amino acid peptide identified in 1995 as the endogenous ligand for the previously orphan receptor ORL-1 (now designated NOP). Structurally, nociceptin shares homology with the classical opioid peptide dynorphin, but the two do not cross-react at their respective receptors: nociceptin does not bind MOR/DOR/KOR with meaningful affinity, and classical opioid peptides do not bind NOP. The NOP receptor signals through the same Gi/Go machinery as the classical opioid receptors — inhibiting adenylyl cyclase, suppressing calcium channels, and activating potassium channels — but its physiological role has proven substantially more complex.

Nociceptin's effects on pain are site-dependent. Supraspinal administration can actually counteract opioid analgesia, while spinal and peripheral NOP activation produces analgesia. This dual action reflects differential NOP distribution across pain-processing circuits. Beyond pain, nociceptin modulates anxiety, stress reactivity, reward, feeding, and memory, and the NOP system has become a focus for novel analgesic drug development precisely because NOP does not couple to the mesolimbic dopamine reward pathway that drives classical opioid addiction.

Two drug-development programs have brought nociceptin-adjacent pharmacology closer to the clinic. Cebranopadol is a mixed NOP/opioid agonist that has shown efficacy in Phase II/III trials for chronic low back pain and cancer pain. Sunobinop, a partial NOP agonist, has been studied for non-REM sleep enhancement. As of 2026, neither drug is approved for general use, but the NOP system's profile — analgesia without classical opioid reward — keeps it at the center of non-addictive pain drug research.

MIF-1 (Pro-Leu-Gly-NH2), also called melanocyte-inhibiting factor-1, is a tripeptide corresponding to the C-terminal three residues of oxytocin after post-translational cleavage. Despite its extraordinarily short sequence, it has been studied for decades as a modulator of central nervous system function, with particular emphasis on dopaminergic potentiation and anti-opioid activity.

The anti-opioid designation is historical but important. MIF-1 and the related Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2) have been reported to attenuate the actions of endogenous and exogenous opioids in several experimental paradigms, operating through mechanisms that are not fully characterized but do not appear to involve direct opioid receptor antagonism. In parallel, MIF-1 has been described as an allosteric modulator of dopamine D2 receptors in the striatum, potentiating dopaminergic signaling without acting as a direct receptor agonist. It may also influence MAO-B activity, oxytocin receptor systems, and GABAergic and serotonergic pathways — a multi-target profile that is characteristic of small regulatory peptides but complicates clean pharmacological interpretation.

The translational story is modest. Small open-label trials in the 1970s and 1980s reported modest improvements in Parkinson's disease motor symptoms following intravenous MIF-1, and rodent studies documented reversal of reserpine-induced akinesia and potentiation of L-DOPA. No modern large-scale randomized trials have been completed, and the compound has remained largely dormant in clinical development since the 1990s. For the purposes of this guide, MIF-1 is best understood as an example of how small peptides derived from larger neuropeptide precursors can retain distinct biological activity — and how a peptide's position in the opioid literature can be shaped as much by historical context as by contemporary mechanistic data.

None of the five peptides profiled here has achieved approved human therapeutic status, and the reasons illustrate why opioid peptide drug development has been unusually difficult. Several themes recur across the catalog.

Pharmacokinetics is the first hurdle. Natural opioid peptides are degraded within minutes by aminopeptidases and other proteases in plasma and brain. The D-alanine substitution in dermorphin extends half-life relative to endogenous peptides, but even dermorphin's approximately 20–30 minute plasma persistence is short by drug-development standards. Modifications such as cyclization, N-methylation, PEGylation, and lipidation can extend peptide half-life, but they often compromise receptor affinity, selectivity, or brain penetration.

The second hurdle is receptor-subtype consequence. Mu-selective analgesics — no matter how potent — carry the familiar respiratory depression and addiction liabilities. Delta-selective agonists have looked promising in preclinical work but have shown convulsive activity in some species. NOP-selective agonists avoid classical opioid reward but bring complex site-dependent effects on pain. Designing a peptide that produces strong analgesia while avoiding every one of these liabilities has proven harder than extrapolating from receptor pharmacology alone would suggest.

The third hurdle is the regulatory and commercial environment for novel analgesics. Following decades of opioid harm, approval pathways for new opioid receptor drugs face elevated scrutiny, and the commercial case for non-opioid peptide analgesics competes with established generics and with non-peptide small molecules. Programs targeting the NOP receptor and mixed NOP/opioid receptor profiles — cebranopadol being the most advanced — represent the current leading edge of attempts to translate opioid-peptide biology into approved therapeutics. The research catalog profiled in this guide underpins those programs; the clinic has yet to catch up.